Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Two Cases of Nivolumab Re-Administration after Pneumonitis as Immune-Related Adverse Events

Blog Article

Nivolumab is a recently approved medication for the treatment of unresectable malignant melanoma.Many immune-related adverse events (irAEs) associated with nivolumab have been reported, such as pneumonitis, hepatitis, dermatitis, and thyroiditis.Prednisolone can effectively treat Circle S Barrel Style Saddle irAEs.However, it is unclear how or if nivolumab should be administered to patients after they have experienced an irAE.

Herein, we show 2 patients who underwent pneumonitis as irAE.Case 1 demonstrated a cryptogenic organizing pneumonia pattern in the CT scan and case 2 had a diffuse alveolar damage (DAD) pattern.Oral corticosteroids improved chest shadow of CT scan in both cases.However, when nivolumab was re-administrated, case 1 demonstrated no symptoms, but Kitchen case 2 demonstrated pneumonia again.

From our cases, it is difficult to re-administrate nivolumab for the patients with pneumonitis which shows a DAD pattern in CT, even if oral corticosteroids improve their symptoms.